|Table of Contents|

Changes of NLR and PLR before and after immunotherapy for non-small cell lung cancer and predictive value for the prognosis of immunotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
613-618
Research Field:
Publishing date:

Info

Title:
Changes of NLR and PLR before and after immunotherapy for non-small cell lung cancer and predictive value for the prognosis of immunotherapy
Author(s):
ZHAO Zhibiao1; BI Minghong1; LI Guoxiang2
1.The First Affiliated Hospital of Bengbu Medical College,Anhui Bengbu 233000,China;2.The No.6 Retreat for Resigning Cadres,Dalian Military Region of Liaoning Province,Liaoning Dalian 116000,China.
Keywords:
NLR; PLR; NSCLC; immunotherapy; progression-free survival
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.04.011
Abstract:
Objective:To investigate the effects of neutrophil to lymphocyte ratio(NLR) and platelet to lymphocyte ratio(PLR) and their dynamic changes on the efficacy and prognosis of non-small cell lung cancer immunotherapy influences.Methods:A retrospective analysis of 32 cases of NSCLC treated with nivolumab in the First Affiliated Hospital of Bengbu Medical College from October 2018 to February 2020 was performed.NLR and PLR before immunotherapy and after two cycles of treatment were collected.Kaplan-Meier method was used for survival analysis.Single factor and Cox multivariate analysis evaluated NLR,PLR and their dynamic changes and the relationship between various clinical features and immunotherapy efficacy and progression-free survival.Results:After immunotherapy,NLR2 decreased significantly compared with NLR0,respectively(3.25±2.80) and (3.94±2.36)(P=0.034 9).PLR2 did not change significantly compared with PLR0,respectively(165.75±114.25) and(197.09±79.90)(P=0.122 0).Univariate analysis showed that PFS was related to NLR0,NLR2,PLR0,PLR2,staging(P＜0.05).Multivariate analysis showed that NLR0(P=0.011),staging(P=0.029) was an independent predictor of PFS factor.Conclusion:Patients with high NLR0 and high PLR0 have shorter PFS,and the dynamic changes of NLR are significantly related to the efficacy of immunotherapy.Therefore,NLR and PLR are ideal indicators to predict the efficacy and prognosis of NSCLC immunotherapy.

References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2] RECK M,RABE KF.Precision diagnosis and treatment for advanced non-small-cell lung cancer［J］.N Engl J Med,2017,377(9):849-861.
[3] HIRSCH FR,SCAGLIOTTI GV,MULSHINE JL,et al.Lung cancer:current therapies and new targeted treatments［J］.Lancet,2017,389(10066):299-311.
[4] AISNER DL,MARSHALL CB.Molecular pathology of non-small cell lung cancer:a practical guide［J］.Am J Clin Pathol,2012,138(3):332-346.
[5] LEE CK,WU YL,DING PN,et al.Impact of specific epidermal growth factor receptor(EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer:A Meta-analysis［J］.J Clin Oncol,2015,33(17):1958-1965.
[6] SCHILLER JH,HARRINGTON D,BELANI CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer［J］.N Engl J Med,2002,346(2):92-98.
[7] KELLY K,CROWLEY J,BUNN PJ,et al.Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a Southwest Oncology Group trial［J］.J Clin Oncol,2001,19(13):3210-3218.
[8] SHER DJ,KOSHY M,LIPTAY MJ,et al.Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base［J］.Cancer,2014,120(13):2060-2068.
[9] ETTINGER DS,WOOD DE,AGGARWAL C,et al.NCCN guidelines insights:non-small cell lung cancer,version 1.2020［J］.J Natl Compr Canc Netw,2019,17(12):1464-1472.
[10] RUSSO A,FRANCHINA T,RICCIARDI G,et al.Baseline neutrophilia,derived neutrophil-to-lymphocyte ratio(dNLR),platelet-to-lymphocyte ratio(PLR),and outcome in non small cell lung cancer(NSCLC) treated with Nivolumab or Docetaxel［J］.J Cell Physiol,2018,233(10):6337-6343.
[11] AMERATUNGA M,CHENARD-POIRIER M,MORENO CI,et al.Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors［J］.Eur J Cancer,2018,89:56-63.
[12] FUKUI T,OKUMA Y,NAKAHARA Y,et al.Activity of Nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer:a prospective observational study［J］.Clin Lung Cancer,2019,20(3):208-214.
[13] ZER A,SUNG MR,WALIA P,et al.Correlation of Neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer［J］.Clin Lung Cancer,2018,19(5):426-434.
[14] MEZQUITA L,AUCLIN E,FERRARA R,et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer［J］.JAMA Oncol,2018,4(3):351-357.
[15] TANIZAKI J,HARATANI K,HAYASHI H,et al.Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with Nivolumab［J］.J Thorac Oncol,2018,13(1):97-105.
[16] BAMBACE NM,HOLMES CE.The platelet contribution to cancer progression［J］.J Thromb Haemost,2011,9(2):237-249.
[17] BAGLEY SJ,KOTHARI S,AGGARWAL C,et al.Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer［J］.Lung Cancer,2017,106:1-7.
[18] DIEM S,SCHMID S,KRAPF M,et al.Neutrophil-to-Lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) as prognostic markers in patients with non-small cell lung cancer(NSCLC) treated with nivolumab［J］.Lung Cancer,2017,111:176-181.
[19] BANNA GL,PASSIGLIA F,COLONESE F,et al.Immune-checkpoint inhibitors in non-small cell lung cancer:A tool to improve patients' selection［J］.Crit Rev Oncol Hematol,2018,129:27-39.
[20] TANIZAKI J,HARATANI K,HAYASHI H,et al.Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with Nivolumab［J］.J Thorac Oncol,2018,13(1):97-105.
[21] DIAKOS CI,CHARLES KA,MCMILLAN DC,et al.Cancer-related inflammation and treatment effectiveness［J］.Lancet Oncol,2014,15(11):e493-e503.
[22] YUAN A,HSIAO YJ,CHEN HY,et al.Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression［J］.Sci Rep,2015,5:14273.
[23] TAO H,MIMURA Y,AOE K,et al.Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells［J］.Lung Cancer,2012,75(1):95-101.
[24] KARGL J,BUSCH SE,YANG GH,et al.Neutrophils dominate the immune cell composition in non-small cell lung cancer［J］.Nat Commun,2017,8:14381.
[25] SAGIV JY,MICHAELI J,ASSI S,et al.Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer［J］.Cell Rep,2015,10(4):562-573.
[26] CHRISTOFFERSSON G,PHILLIPSON M.The neutrophil:one cell on many missions or many cells with different agendas［J］.Cell Tissue Res,2018,371(3):415-423.
[27] GU X,SUN S,GAO XS,et al.Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer:evidence from 3,430 patients［J］.Sci Rep,2016,6:23893.
[28] SODA H,OGAWARA D,FUKUDA Y,et al.Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer:A hypothesis-generating study［J］.Thorac Cancer,2019,10(2):341-346.
[29] TAN Q,LIU S,LIANG C,et al.Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors:A meta-analysis［J］.Thorac Cancer,2018,9(10):1220-1230.
[30] MEZQUITA L,AUCLIN E,FERRARA R,et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer［J］.JAMA Oncol,2018,4(3):351-357.
[31] RUSSO A,RUSSANO M,FRANCHINA T,et al.Neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and outcomes with Nivolumab in pretreated non-small cell lung cancer(NSCLC):A large retrospective multicenter study［J］.Adv Ther,2020,37(3):1145-1155.
[32] LIU J,LI S,ZHANG S,et al.Systemic immune-inflammation index,neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab［J］.J Clin Lab Anal,2019,33(8):e22964.
[33] DIEM S,SCHMID S,KRAPF M,et al.Neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) as prognostic markers in patients with non-small cell lung cancer(NSCLC) treated with nivolumab［J］.Lung Cancer,2017,111:176-181.

Memo

Memo:
安徽省高校自然科学研究项目（编号：KJ2019A0372）
Last Update: 1900-01-01